Tiffany Murrell
Family · Jasper, INNPI 1871090100
Payments from drug & device makers
Across 189 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$724
- MDD US Operations, LLC$229
- Eisai Inc.$142
- Novartis$136
- UCB, Inc.$129
- Lilly USA, LLC$122
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,008100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 74 | $724 |
| MDD US Operations, LLC | 2 | $229 |
| Eisai Inc. | 6 | $142 |
| Novartis | 8 | $136 |
| UCB, Inc. | 6 | $129 |
| Lilly USA, LLC | 7 | $122 |
| AstraZeneca | 6 | $116 |
| Biogen | 4 | $107 |
| EMD Serono, Inc. | 6 | $101 |
| Amneal Pharmaceuticals LLC | 5 | $93 |
| Lundbeck LLC | 5 | $81 |
| Pfizer | 5 | $78 |
| Teva Pharmaceuticals USA, Inc. | 4 | $69 |
| ANI Pharmaceuticals, Inc. | 4 | $68 |
| Banner Life Sciences, LLC | 3 | $66 |
| Livanova USA, Inc. | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Amgen | 3 | $46 |
| Johnson & Johnson | 3 | $45 |
| Argenx US, Inc. | 2 | $44 |
| Sunovion Pharmaceuticals Inc. | 6 | $42 |
| SK Life Science, Inc. | 2 | $42 |
| Genentech USA, Inc. | 2 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Bristol Myers Squibb | 2 | $33 |
| Globus Medical | 1 | $32 |
| Neurelis, Inc. | 2 | $32 |
| Boston Scientific | 2 | $31 |
| TG Therapeutics, Inc. | 2 | $29 |
| Sanofi | 2 | $27 |
| Catalyst Pharmaceuticals, Inc. | 1 | $24 |
| Nevro Corp. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| CSL Behring | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- APOKYN$212
How this compares
$3,008 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 56 | $544,379 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $508,316 |
| MayzentSiponimod | 13 | $120,013 |
| AubagioTeriflunomide | 12 | $110,351 |
| EpidiolexCannabidiol (Cbd) | 16 | $53,124 |
| RytaryCarbidopa/Levodopa | 41 | $52,210 |
| QuliptaAtogepant | 42 | $47,084 |
| UbrelvyUbrogepant | 40 | $38,719 |
| EliquisApixaban | 43 | $35,785 |
| Aimovig AutoinjectorErenumab-Aooe | 40 | $33,916 |
| Nurtec OdtRimegepant Sulfate | 27 | $27,702 |
| Emgality PenGalcanezumab-Gnlm | 20 | $14,832 |
| Pregabalin | 419 | $9,635 |
| Dalfampridine ErDalfampridine | 34 | $6,928 |
| MyrbetriqMirabegron | 14 | $6,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $22 | $508,31613 claims |
| NovartisMayzent | $136 | $120,01313 claims |
| SanofiAubagio | $27 | $110,35112 claims |
| AbbVieQulipta, Ubrelvy | $724 | $85,80382 claims |
| PfizerEliquis, Nurtec Odt | $78 | $63,48770 claims |
| Amneal Pharmaceuticals LLCRytary | $93 | $52,21041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.
Other family in Jasper
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.